Leading in times of crisis: Yale physicians on team dynamics and effective leadership
Tariq Ahmad MD, MPH and John K. Forrest, MD discuss their past experiences with the American College of Cardiology’s (ACC) leadership development programs and how academic medical centers can navigate the global pandemic.
Dr. Nassiri is selected to the International Society for Study of Vascular Anomalies (ISSVA) task force on classification of vascular anomalies
Dr. Nassiri is selected to represent the United States and the Specialty of Vascular Surgery on the International Society for Study of Vascular Anomalies (ISSVA) Ad-hoc Committee for Classification of Vascular Anomalies.Source: ISSVA Newsletter Vol 5 - No 1 | April 2021
Outcomes Worse in Patients with Persistent Conduction Abnormalities after TAVR
Recent advances in TAVR have enabled lower-risk patients to benefit from this therapy. However, post-TAVR complications with the heart’s electrical impulses, known as conduction abnormalities, continue to undermine the next generation of valve repair devices.
The Yale Vascular Malformations Program (VaMP) identifies a culprit gene mutation implicated in the pathogenesis of "hepatic hemangiomas".
The Yale New Haven Hospital Vascular Malformations Program (VaMP), via a collaborative multidisciplinary effort, has identified somatic mosaic gene mutations (GJA4 encoding connexin 37) implicated in the pathogenesis of so-called “HEPATIC HEMANGIOMAS” in adult patients. This discovery questions the validity of the very term “hemangioma” in this particular anatomic distribution; and renders – for the first time - objective scientific support to the radiographically and clinically suspected notion that these lesions actually represent VENOUS MALFORMATIOMS - an entity with a completely different natural history, hemodynamics, angioarchitectural profile, and ergo therapeutic susceptibility.Source: Cutaneous and hepatic vascular lesions due to a recurrent somatic GJA4 mutation reveal a pathway for vascular malformation
Strategies to accelerate diagnosis and treatment of rare cardiovascular diseases
The current landscape for patients with rare cardiovascular disease has shifted. Using genome sequencing Yale physician-scientists have begun to elucidate the pathophysiology of genetic disorders and develop treatment guidelines and recommendations.